KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EBITDA: 2009-2025

Historic EBITDA for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $1.5 billion.

  • Regeneron Pharmaceuticals' EBITDA rose 0.39% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 6.23%. This contributed to the annual value of $4.5 billion for FY2024, which is 9.10% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its EBITDA stood at $1.5 billion for Q3 2025, which was up 4.35% from $1.4 billion recorded in Q2 2025.
  • Regeneron Pharmaceuticals' 5-year EBITDA high stood at $3.1 billion for Q2 2021, and its period low was $725.7 million during Q1 2024.
  • For the 3-year period, Regeneron Pharmaceuticals' EBITDA averaged around $1.1 billion, with its median value being $1.0 billion (2023).
  • In the last 5 years, Regeneron Pharmaceuticals' EBITDA soared by 228.95% in 2021 and then slumped by 74.23% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBITDA (Quarterly) stood at $2.2 billion in 2021, then tumbled by 43.77% to $1.2 billion in 2022, then increased by 1.79% to $1.3 billion in 2023, then plummeted by 32.33% to $849.6 million in 2024, then increased by 0.39% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $845.7 million during Q1 2025.